BeyondSpring says FDA Fast Track for plinabulin with docetaxel in NSCLC Phase 3

BeyondSpring said the FDA granted Fast Track status for plinabulin with docetaxel in later-line advanced non-squamous NSCLC without actionable genomic alterations. The designation supports its global Phase 3 DUBLIN-4 study, with next readout planned at interim analysis tied to disease-progression events; a China-focused deal shifts funding for about half of 442 planned patients to an outside investor.